 | |
| Clinical data | |
|---|---|
| Other names | CIN-102; deuterated domperidone; domperidone deuterated |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H20ClD4N5O2 |
| Molar mass | 429.94 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deudomperidone (developmental code nameCIN-102; also known asdeuterated domperidone) is adopamine antagonist medication which is under development in theUnited States for the treatment ofgastroparesis.[1][2][3] It acts as aselectivedopamineD2 andD3 receptorantagonist and hasperipheral selectivity.[2][3] Deudomperidone is adeuterated form ofdomperidone, and it is suggested that deudomperidone may have improvedefficacy,tolerability, andpharmacokinetics compared to domperidone.[2][3] As of January 2022, deudomperidone is inphase 2clinical trials for the treatment of gastroparesis.[1]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byadding missing information. |
